首页> 美国卫生研究院文献>other >Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised two-by-two factorial phase 3 study

【2h】

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised two-by-two factorial phase 3 study

机译：IIIA期或IIIB期非小细胞肺癌（RTOG 0617）患者的标准剂量与大剂量适形放疗联合或合并卡铂联合紫杉醇联合西妥昔单抗联合或不联合西妥昔单抗研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 other
作者
Prof. Jeffrey D Bradley; Rebecca Paulus; Prof. Ritsuko Komaki; Gregory Masters; Prof. George Blumenschein; Prof. Steven Schild; Prof. Jeffrey Bogart; Chen Hu; Kenneth Forster; Prof. Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Prof. Raymond B Wynn; Christopher Koprowski; Joanne Meng; Prof. Jonathan Beitler; Rakesh Gaur; Prof. Walter Curran Jr; Prof. Hak Choy;
展开▼
作者单位

展开▼
年(卷),期 -1(16),2
年度 -1
页码 187–199
总页数 22
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J] . Bradley Jeffrey D., Paulus Rebecca, Komaki Ritsuko, The lancet oncology . 2015,第2期

机译：IIIA期或IIIB期非小细胞肺癌（RTOG 0617）患者的标准剂量与大剂量适形放疗联合或合并卡铂联合紫杉醇联合西妥昔单抗联合或不联合西妥昔单抗研究
2. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer [J] . Bradley Jeffrey D., Hu Chen, Komaki Ritsuko R., Journal of Clinical Oncology . 2020,第7期

机译：NRG肿瘤学的长期结果RTOG 0617：标准 - 与高剂量化学疗法，有或没有Cetuximab用于不可选择的阶段III非小细胞肺癌
3. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. [J] . Stinchcombe TE, Morris DE, Lee CB, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2008,第3期

机译：不可切除的IIIA期和IIIB期非小细胞肺癌患者先用卡铂，伊立替康和紫杉醇诱导化疗，然后进行高剂量三维保形胸放疗（74 Gy）并用卡铂，紫杉醇和吉非替尼。
4. Phase 2 Study of Pemetrexed plus Carboplatin or Pemetrexed plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer [O] . Hak Choy, Lee S. Schwartzberg, Shaker R. Dakhil, -1

机译：培美曲塞加卡铂或培美曲塞加顺铂并发放射治疗后培美曲塞合并巩固治疗的III-A / B期非小细胞肺癌患者预后良好
5. Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer [O] . Stinchcombe Thomas E., Morris David E., Lee Carrie B., 2008

机译：不可切除的IIIA期和IIIB期非小细胞肺癌患者先后用卡铂，伊立替康和紫杉醇进行诱导化学疗法，然后进行大剂量三维共形胸廓放疗（74 Gy），并用卡铂，紫杉醇和吉非替尼。

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised two-by-two factorial phase 3 study

著录项

相似文献

相关主题

期刊订阅